MBio Diagnostics Company
MBio Diagnostics is the innovator of the proprietary point-of care LightDeck® platform that delivers highly sensitive, lab-quality results in minutes. The LightDeck platform consists of a robust, portable fluorescence analyzer and disposable, multiplex test cartridges. The test procedure is simple, enabling untrained users to perform testing on-the-spot. Brava Diagnostics, the IVD division of MBio, is developing a portfolio of multiplex tests including panels for COVID-19, host-response panels for acute infections and sepsis and panels of cardiac markers for heart attack and heart failure. The LightDeck platform is also commercialized for veterinary diagnostics and for environmental testing.
Technology:
P4 Medicine
Industry:
Biotechnology, Health Care, Health Diagnostics
Headquarters:
Boulder, Colorado, United States
Founded Date:
2009-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Acquisitions Number:
1
Investors Number:
1
Total Funding:
$18M
Estimated Revenue:
$1M to $10M
Last Funding Type:
Series B
Register and Claim Ownership